HOOK (HOOKIPA Pharma) YoY EPS Growth: 90.75% (As of Jun. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HOOK HOOKIPA Pharma Inc HOOK
50 GF Score
Price $1.15
View Full Analysis

What is HOOKIPA Pharma YoY EPS Growth?

HOOKIPA Pharma HOOK 50 YoY EPS Growth is 90.75% as of Jun. 2025. GuruFocus rates HOOK with a GF Score™ of 50/100.

YoY EPS Growth is the percentage change of Earnings per Share (Diluted) over the past twelve months. HOOKIPA Pharma's YoY EPS Growth for the quarter that ended in Jun. 2025 was 90.75%.

HOOKIPA Pharma's Earnings per Share (Diluted) for the three months ended in Jun. 2025 was $-0.14.

HOOKIPA Pharma YoY EPS Growth Historical Data

* Premium members only.

The historical data trend for HOOKIPA Pharma's YoY EPS Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

HOOKIPA Pharma YoY EPS Growth Chart

HOOKIPA Pharma Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
YoY EPS Growth
Get a 7-Day Free Trial 29.75 -36.13 57.00 12.90 59.80

HOOKIPA Pharma Quarterly Data
Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25
YoY EPS Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 30.09 36.09 17.48 -207.71 90.75
HOOK
50GF Score
HOOKIPA Pharma Inc HOOK
YoY EPS Growth is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

HOOKIPA Pharma YoY EPS Growth Calculation

YoY EPS Growth is the percentage change of Earnings per Share (Diluted) over the past twelve months.

HOOKIPA Pharma's YoY EPS Growth for the fiscal year that ended in Dec. 2024 is calculated as:

YoY EPS Growth (A: Dec. 2024 )
=(Earnings per Share (Diluted) (A: Dec. 2024 )-Earnings per Share (Diluted) (A: Dec. 2023 ))/ | Earnings per Share (Diluted) (A: Dec. 2023 ) |
=(-3.4695--8.6304)/ | -8.6304 |
=59.80 %

HOOKIPA Pharma's YoY EPS Growth for the quarter that ended in Jun. 2025 is calculated as:

YoY EPS Growth (Q: Jun. 2025 )
=(Earnings per Share (Diluted) (Q: Jun. 2025 )-Earnings per Share (Diluted) (Q: Jun. 2024 )) / | Earnings per Share (Diluted) (Q: Jun. 2024 )) |
=(-0.1408--1.5229)/ | -1.5229 |
=90.75 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about YoY EPS Growth →
What does a YoY EPS Growth of 90.75% mean?
HOOKIPA Pharma (HOOK) has a YoY EPS Growth of 90.75% as of Jun. 2025. YoY EPS Growth is the percentage change of EPS over the past 12-month. View historical data for HOOKIPA Pharma and its competitors.
Is HOOKIPA Pharma's YoY EPS Growth too high?
HOOKIPA Pharma's current YoY EPS Growth is 90.75%. Overall, HOOKIPA Pharma has a GF Score™ of 50/100, reflecting its overall financial health beyond just this single metric.
How does HOOKIPA Pharma's YoY EPS Growth compare to COCP and LNAI?
HOOKIPA Pharma's YoY EPS Growth of 90.75% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good YoY EPS Growth for a Biotechnology company?
A good YoY EPS Growth depends on the Biotechnology industry context. However, YoY EPS Growth should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high YoY EPS Growth mean?
A high YoY EPS Growth can signal that a stock is expensive relative to its fundamentals. YoY EPS Growth is the percentage change of EPS over the past 12-month. View historical data for HOOKIPA Pharma and its competitors. HOOKIPA Pharma's current YoY EPS Growth is 90.75%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is HOOKIPA Pharma stock overvalued right now?
HOOKIPA Pharma (HOOK) has a current YoY EPS Growth of 90.75%. The current YoY EPS Growth is 90.75%. HOOKIPA Pharma's overall GF Score™ is 50/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is YoY EPS Growth calculated?
YoY EPS Growth is calculated from a company's financial statements. For HOOKIPA Pharma (HOOK), the current YoY EPS Growth is 90.75% as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

HOOKIPA Pharma Business Description

Address 350 Fifth Avenue, 72nd Floor, Suite 7240, New York, NY, USA, 10118
HOOKIPA Pharma Inc is a clinical-stage biopharmaceutical company developing a class of immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform that is designed to reprogram the body's immune system. The company's product candidates are designed to induce specific, robust and durable CD8+ T cells and antibodies to eliminate cancers and serious infectious diseases. Its pipeline includes biological therapies for oncology, targeting human papillomavirus type 16-positive (HPV16+) cancers, KRAS mutated cancers, and other targets. In addition, It is also focused to develop therapies that are intended to provide functional cures for hepatitis B virus (HBV) and human immunodeficiency virus-1 (HIV-1).
50GF Score

Get the complete analysis for HOOK

YoY EPS Growth is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.15
Price